Related Experiment Videos
Ritanserin and alcohol abuse and dependence
1Janssen Research Foundation, Department of Neuropsychopharmacology, Beerse, Belgium.
Alcohol and Alcoholism (Oxford, Oxfordshire). Supplement
|January 1, 1994
Summary
Ritanserin, a 5-HT2 antagonist, shows promise in treating alcohol dependence by reducing alcohol intake and withdrawal symptoms. Clinical trials are underway to further evaluate its efficacy and safety in alcohol-dependent patients.
Area of Science:
- Neuroscience
- Pharmacology
- Psychiatry
Background:
- Ritanserin is a potent, long-acting central 5-HT2 antagonist.
- It has demonstrated benefits in psychiatric disorders and sleep.
- Unexpected clinical observations suggested potential in treating drug addiction and alcohol withdrawal.
Purpose of the Study:
- To investigate the potential of ritanserin as a pharmacological treatment for alcohol abuse and dependence.
- To evaluate ritanserin's effects on alcohol intake, preference, and withdrawal symptoms.
Main Methods:
- Four experiments were conducted to assess ritanserin's efficacy in various models.
- Studies included evaluating abuse potential, direct ethanol interaction, alcohol intake reduction, and effects on the dopaminergic pathway.
- Clinical development involved safety studies and trials in heavy social drinkers and alcohol-dependent patients.
Main Results:
- Ritanserin demonstrated no abuse potential and no direct interaction with ethanol.
- It was shown to reduce alcohol intake and preference in various models.
- Ritanserin reduced some alcohol withdrawal signs and influenced the desire to drink in heavy social drinkers.
Conclusions:
- Ritanserin shows significant potential as a pharmacological treatment for alcohol abuse and dependence.
- Further clinical development is supported by preclinical and early clinical findings.
- Ongoing large-scale trials are evaluating its efficacy in diverse alcohol-dependent populations.